Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2006-10-03
2006-10-03
Lewis, Patrick (Department: 1623)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C514S054000, C514S930000, C536S018700, C536S055200, C536S123100
Reexamination Certificate
active
07115588
ABSTRACT:
The present invention relates to compositions comprising semi-crystalline β-1-4-N-acetylglucosamine polymers (p-GlcNac) and methods utilizing such polymers modulation of vascular structure and/or function. The compositions and methods disclosed are useful for stimulating, in a p-GlcNac concentration-dependent manner, endothelin-1 release, vasoconstriction, and/or reduction in blood flow out of a breached vessel, as well as for contributing to or effecting cessation of bleeding. The methods of the present invention comprise topical administration of materials comprising semi-crystalline p-GlcNac polymers that are free of proteins, and substantially free of single amino acids as well as other organic and inorganic contaminants, and whose constituent monosaccharide sugars are attached in a β-1-4 conformation.
REFERENCES:
patent: 4394373 (1983-07-01), Malette et al.
patent: 5219749 (1993-06-01), Bouriotis et al.
patent: 5437292 (1995-08-01), Kipshidze et al.
patent: 5443481 (1995-08-01), Lee
patent: 5510102 (1996-04-01), Cochrum et al.
patent: 5622834 (1997-04-01), Vournakis et al.
patent: 5623064 (1997-04-01), Vournakis et al.
patent: 5624679 (1997-04-01), Vournakis et al.
patent: 5631019 (1997-05-01), Marx
patent: 5635493 (1997-06-01), Vournakis et al.
patent: 5645849 (1997-07-01), Pruss et al.
patent: 5686115 (1997-11-01), Vournakis et al.
patent: 5728132 (1998-03-01), Van Tassel et al.
patent: 5746755 (1998-05-01), Wood et al.
patent: 5814066 (1998-09-01), Spotnitz
patent: 5846952 (1998-12-01), Vournakis et al.
patent: 5855559 (1999-01-01), Van Tassel et al.
patent: 5858350 (1999-01-01), Vournakis et al.
patent: 5897860 (1999-04-01), Kim et al.
patent: 5990079 (1999-11-01), Wolf et al.
patent: 6033427 (2000-03-01), Lee
patent: 6056970 (2000-05-01), Greenawalt et al.
patent: 6063911 (2000-05-01), Vournakis et al.
patent: 6193670 (2001-02-01), Van Tassel et al.
patent: 6334865 (2002-01-01), Redmond et al.
patent: 6361551 (2002-03-01), Torgerson et al.
patent: 2002/0006429 (2002-01-01), Redmond et al.
Alsip et al., 1996, “A new technique for studying the uterine microvasculature in the rat”, Am. J. Obstet. Gynecol. 175:388-395.
Austin and Sennett, 1986, “Dry chitosan salts and complexes of aliphatic carboxylic acids”, in:Chitin in Nature and Technology,Muzzarelli et al., eds., Plenum Press, New York, pp. 279-286.
Barton and Luscher, 1999, “Endothelin antagonists for hypertension and renal disease”, Curr. Opin. Nephrol. Hypertens. 8:549-556.
Becker et al., 2000, “Endothelial function and hemostasis”, Z. Kardiol. 89:160-167.
Brooks et al., 1991, “Effect of nifedipine on cylosporine A-induced nephrotoxicity, urinary endothelin excretion and renal endothelin receptor number”, Eur. J. Pharmacol. 194:115-117.
Caron et al., 1998, “Proposition of a technique to assess the vasoactive effects of hemoglobin-based oxygen carrying solutions in vivo: preliminary results in the rabbit aorta”, Artif. Cells Blood Substit. Immobil. Biotechnol. 26:293-308.
Davidson et al., 2000, “Experimental study of a novel fibrin sealant for archieving haemostasis following partial hepatectomy”, Br. J. Surg. 87:790-795.
Davis and Preston, 1981, “A simple modified carbodimide method for conjugation of small-molecular-weight compounds to immunoglobulin G with minimal protein crosslinking”, Anal. Biochem. 116:402-407.
Domard, 1986, “Circular dichroism study on N-acetylgucosamine oligomers”, Int. J. Biol. Macromol. 8:243-246.
Dupuis, 2000, “Endothelin receptor antagonists and their developing role in cardiovascular therapeutics”, Can. J. Cardiol. 16:903-910.
Emerson et al., 1999, “Endogenous nitric oxide acts as a natural antithrombolic agent in vivo by inhibiting platelet aggregation in the pulmonary vasculature”, Thromb. Haemost. 81:961-966.
Goldie, 1999, “Endothelins in health and disease: an overview”, Clin. Exp. Pharmacol. Physiol. 26:145-148.
Guo et al., 1994, “Endothelial preserving actions of a nitric oxide donor in carotid arterial intimal injury”, Methods Find. Exp. Clin. Pharmacol. 15:347-354.
Hirano, 1989, “Production and application of chitin and chitosan in Japan”, inChitin and Chitosan,Skjak-Brack et al., eds., Elsevier Science Publishing Co., pp. 37-43.
Hirano et al., 1981, “SEM ultrastructure studies of N-acyl- and N-benzylidene-chitosan and chitosan membranes”, J. Biomed. Mater. Res. 15:903-911.
Hirano et al., 1976, “Selective N-acylation of chitosan”, Carbohydrate Res. 47:315-320.
Hocher et al., 1997, “The paracrine endothelin system: pathophysiology and implications in clinical medicine”, Eur. J. Clin. Chem. Clin. Biochem. 35:175-189.
Inoue et al., 1989, “The human endothelin family: three structurally and pharmacologically distinct isopeptides predicted by three separate genes”, Proc. Natl. Acad. Sci. USA 86:2863-2867.
Ishida et al., 1989, “Differential activities of two distinct endothelin family peptides on ileum and coronary artery”, FEBS Lett. 247:337-340.
Kashiwabara et al., 1989, “Putative precursors of endothelin have less vasoconstrictor activity in vitro but a potent pressor effect in vivo”, FEBS Lett. 247:73-76.
Kim and Greenburg, 2000, “Pharmacodynamic characterization of hemoglobin-induced vasoactivity in isolated rat thoracic aorta”, J. Lab. Clin. Med. 135:180-187.
Komai et al., 1986, “Biomedical evaluation of acylated chitins as coating materials”, in:Chitin in Nature and Technology,Muzzarelli et al., eds., Plenum Press, New York, pp. 497-506.
Kurita et al., 1990, “Preparations of soluble chitin derivatives and the modifications to branched chitins”, Polymer Prep. 31:624-625.
Kurita and Inoue, 1989, “Preparation of indo-chitins and graft copolymerization onto the derivatives”, in:Chitin and Chitosan,Skjak-Brack et al., eds., Elsevier Science Publishing Co., p. 365.
Lüscher and Wenzel, 1995, “Endothelin and endothelin antagonist: pharmacology and clinical implications”, Agents Actions Suppl. 45:237-253.
Maresh et al., 1989, “Hydroxypropylation of chitosan”, in:Chitin and Chitosan,Skjak-Brack et al., eds., Elsevier Science Publishing Co., pp. 389-395.
Mireless et al., 1992, “Complex formation of chitosan and naturally occurring polyanion”, in:Advances in Chitin and Chitosan,Brine et al., eds., Elsevier Publishers, Ltd., pp. 506-515.
Nishi et al., 1986, “Preparation and characterization of phosphorylated chitin and chitosan”, in:Chitin in Nature and Technology,Muzzarelli et al., eds., Plenum Press, New York, pp. 297-299.
Noguchi et al., 1969, “Chitosan epichlorohydrin anion exchange resin with primary amine as absorption site”, Kogyo Kagaku Zasshi 72:796-799 (in Japanese with English abstract).
Ortega Mateo and de Artinano, 1997, “Highlights on endothelins: a review”, Pharmacological Res. 36:339-351.
Pasricha et al., 1999, “Endoscopic cryotherapy: experimental results and first clinical use”, Gastrointest. Endosc. 49:627-631.
Pearson, 2000, “Normal endothelial cell function”, Lupus 9:183-188.
Rosendorff, 1996, “Endothelin, vascular hypertrophy, and hypertension”, Cardiovasc. Drugs Ther. 10:795-802.
Saida et al., 1989, “A novel peptide, vasoactive intestinal contractor, of a new (endothelin) peptide family. Molecular cloning, expression, and biological activity”, J. Biol. Chem. 264:14613-14616.
Salamonsen et al., 1999, “Current concepts of the mechanisms of menstruation”, Balliére's Best Pract. Res. Clinical Obstetrics and Gynaecology 13:161-179.
Salamonsen et al., 1999, “Endometrial endothelin: regulator of uterine bleeding and endometrial repair”, Clin. Exp. Pharmacol. Physiol. 26:154-157.
Schiffrin et al., 1995, “Antihypertensive effect of an endothelin recep
Finkielsztein Sergio
Vournakis John N.
Jones Day
Lewis Patrick
Marine Polymer Technologies Inc.
LandOfFree
Methods for treating a breach or puncture in a blood vessel does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for treating a breach or puncture in a blood vessel, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for treating a breach or puncture in a blood vessel will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3682206